GSK is the first to raise the functional cure rate with its antisense drug, Phase II data suggest, but the company is looking for ways to boost responses across hepatitis B patients in its Phase III study.

The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.

Pfizer, Merck, Eli Lilly and Gilead all benefited from the sale of vaccines and treatments for COVID-19, but the long-term growth prospects remain uncertain, and more so for some than others.

The Danish firm’s GLP-1 drugs are behind much of its 2021 sales success as ongoing problems with the manufacturing of in-demand obesity product Wegovy dampen growth.